Ep. 228 - Energizing Gene Therapy. Plus: AI Newco, Ono-Deciphera

Led by CBER Director Peter Marks, FDA is moving forward with policies that aim to improve access to gene therapies for patients with rare diseases. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how FDA plans to use regulatory policies to overcome barriers that are slowing gene therapy, as well as how Pfizer hopes to ensure access to its newly approved hemophilia gene therapy. The editors also assess the $2.4 billion acquisition of Massachusetts oncology company Deciphera by Japan’s Ono as it seeks to diversify its pipeline beyond Opdivo and expand its global footprint. They also discuss the $1 billion launch of AI-guided therapeutics developer Xaira. Finally, BioCentury’s Joshua Berlin joins the podcast to preview BioCentury’s upcoming conference Bio€quity Europe, which kicks off May 12 in San Sebastián. This week’s podcast is sponsored by Jeito Capital. View full story: https://www.biocentury.com/article/6522730:01 - Sponsor Message: Jeito Capital1:55 - Energizing Gene Therapy6:28 - Pfizer Hemophilia Approval11:36 - Bio€quity Europe Preview18:03 - Arch & Foresite's AI Biotech Build19:32 - Ono's Deciphera Takeout